published meta-analysis   sensitivity analysis   studies

anticoagulant, prophylactic dose in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 1.14 [0.83; 1.56] COALIZAO ACTION, 2021 (REV) 0.64 [0.37; 1.12] COVID-PACT, 2022 (REV) 1.10 [0.68; 1.79] INSPIRATION, 2021 (REV) 0.92 [0.66; 1.28] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 0.92 [0.72; 1.18] 0.96[0.82; 1.12]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV), COALIZAO ACTION, 2021 (REV), COVID-PACT, 2022 (REV), INSPIRATION, 2021 (REV), REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV)50%4,882moderatenot evaluable clinical deteriorationdetailed resultsCOALIZAO ACTION, 2021 (REV) 0.74 [0.46; 1.18] 0.74[0.46; 1.18]COALIZAO ACTION, 2021 (REV)10%615NAnot evaluable clinical improvementdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 1.20 [0.97; 1.49] 1.20[0.97; 1.49]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV)10%1,074NAnot evaluable clinical improvement (28-day)detailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 0.79 [0.64; 0.98] 0.79[0.64; 0.98]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV)10%2,219NAnot evaluable death or ventilationdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 1.22 [0.94; 1.59] 1.22[0.94; 1.59]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV)10%2,231NAnot evaluable Major thrombotic events or deathdetailed resultsCOVID-PACT, 2022 (REV) 1.79 [1.02; 3.14] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 0.96 [0.74; 1.26] 1.24[0.68; 2.26]COVID-PACT, 2022 (REV), REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV)273%1,473moderatenot evaluable Major bleedingdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 0.56 [0.27; 1.13] COALIZAO ACTION, 2021 (REV) 0.40 [0.12; 1.29] COVID-PACT, 2022 (REV) 0.26 [0.03; 2.29] INSPIRATION, 2021 (REV) 0.55 [0.16; 1.88] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 0.68 [0.34; 1.36] 0.55[0.36; 0.85]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV), COALIZAO ACTION, 2021 (REV), COVID-PACT, 2022 (REV), INSPIRATION, 2021 (REV), REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV)50%4,876moderateserious Thromboembolic eventsdetailed resultsCOALIZAO ACTION, 2021 (REV) 1.37 [0.77; 2.41] INSPIRATION, 2021 (REV) 0.94 [0.67; 1.31] 1.05[0.75; 1.48]COALIZAO ACTION, 2021 (REV), INSPIRATION, 2021 (REV)221%1,176moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-10-31 23:53 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 829 - roots T: 290